Zscan4 promotes genomic stability during reprogramming and dramatically improves the quality of iPS cells as demonstrated by tetraploid complementation

Cell Research

Volumn 23, Issue 1, 2013, Pages 92-106

  Jiang, Jing ^a   Lv, Wenjian ^a   Ye, Xiaoying ^b   Wang, Lingbo ^a   Zhang, Man ^a   Yang, Hui ^a   Okuka, Maja ^c   Zhou, Chikai ^a   Zhang, Xuan ^a   Liu, Lin ^b   Li, Jinsong ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b NANKAI UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Genomic stability; iPS cells; Somatic reprogramming; Telomere; Tetraploid complementation; Zscan4

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR; ZSCAN4F PROTEIN, MOUSE;

ANIMAL; ARTICLE; CELL CULTURE; CYTOLOGY; DNA REPAIR; GENETIC TRANSFECTION; GENETICS; GENOMIC INSTABILITY; HUMAN; METABOLISM; MOUSE; NUCLEAR REPROGRAMMING; PATHOLOGY; PLURIPOTENT STEM CELL; TELOMERE; TERATOMA; TETRAPLOIDY;

ANIMALS; CELLS, CULTURED; DNA REPAIR; GENOMIC INSTABILITY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; NUCLEAR REPROGRAMMING; TELOMERE; TERATOMA; TETRAPLOIDY; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

IPS; MUS;

EID: 84872037931     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2012.157     Document Type: Article

References (62)

1. Hochedlinger K, Plath K. Epigenetic reprogramming and induced pluripotency. Development 2009; 136: 509-523.
2. Pera MF. Stem cells: The dark side of induced pluripotency. Nature 2011; 471: 46-47.
3. Gonzalez F, Boue S, Izpisua Belmonte JC. Methods for making induced pluripotent stem cells: reprogramming à la carte. Nat Rev Genet 2011; 12: 231-242.
4. Bar-Nur O, Russ HA, Efrat S, Benvenisty N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 2011; 9: 17-23.
5. Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467: 285-290.
6. Kim K, Zhao R, Doi A, et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol 2011; 29: 1117-1119.
7. Polo JM, Liu S, Figueroa ME, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010; 28: 848-855.
8. Stadtfeld M, Apostolou E, Akutsu H, et al. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010; 465: 175-181.
9. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-67.
10. Hussein SM, Batada NN, Vuoristo S, et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471: 58-62.
11. Laurent LC, Ulitsky I, Slavin I, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011; 8: 106-118.
12. Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471: 68-73.
13. Mayshar Y, Ben-David U, Lavon N, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010; 7: 521-531.
14. Kawamura T, Suzuki J, Wang YV, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009; 460: 1140-1144.
15. Marion RM, Strati K, Li H, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009; 460: 1149-1153.
16. Hong H, Takahashi K, Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009; 460: 1132-1135.
17. Sarig R, Rivlin N, Brosh R, et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med 2010; 207: 2127-2140.
18. Zhao XY, Li W, Lv Z, et al. iPS cells produce viable mice through tetraploid complementation. Nature 2009; 461: 86-90.
19. Kang L, Wang J, Zhang Y, Kou Z, Gao S. iPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell 2009; 5: 135-138.
20. Brambrink T, Hochedlinger K, Bell G, Jaenisch R. ES cells derived from cloned and fertilized blastocysts are transcriptionally and functionally indistinguishable. Proc Natl Acad Sci USA 2006; 103: 933-938. (Pubitemid 43212199)
21. Wakayama S, Jakt ML, Suzuki M, et al. Equivalency of nuclear transfer-derived embryonic stem cells to those derived from fertilized mouse blastocysts. Stem Cells 2006; 24: 2023-2033. (Pubitemid 44477127)
22. Yang X, Smith SL, Tian XC, Lewin HA, Renard JP, Wakayama T. Nuclear reprogramming of cloned embryos and its implications for therapeutic cloning. Nat Genet 2007; 39: 295-302. (Pubitemid 46328492)
23. Falco G, Lee SL, Stanghellini I, Bassey UC, Hamatani T, Ko MS. Zscan4: a novel gene expressed exclusively in late 2-cell embryos and embryonic stem cells. Dev Bio 2007; 307: 539-550. (Pubitemid 47001364)
24. McKinnon PJ, Caldecott KW. DNA strand break repair and human genetic disease. Annu Rev Genomics Hum Genet 2007; 8: 37-55.
25. Lukas J, Lukas C, Bartek J. More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol 2011; 13: 1161-1169.
26. Bonner WM, Redon CE, Dickey JS, et al. GammaH2AX and cancer. Nat Rev Cancer 2008; 8: 957-967.
27. Hirata T, Amano T, Nakatake Y, et al. Zscan4 transiently reactivates early embryonic genes during the generation of induced pluripotent stem cells. Sci Rep 2012; 2:208.
28. Zalzman M, Falco G, Sharova LV, et al. Zscan4 regulates telomere elongation and genomic stability in ES cells. Nature 2010; 464: 858-863.
29. de Lange T. How telomeres solve the end-protection problem. Science 2009; 326: 948-952.
30. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 13: 1549-1556. (Pubitemid 37078413)
31. Su TT. Cellular responses to DNA damage: one signal, multiple choices. Annu Rev Genet 2006; 40: 187-208. (Pubitemid 44956784)
32. Ikbal M, Atasoy M, Pirim I, Aliagaoglu C, Karatay S, Erdem T. The alteration of sister chromatid exchange frequencies in Behcet's disease with and without HLA-B51. J Eur Acad Dermatol Venereol 2006; 20: 149-152. (Pubitemid 43740513)
33. Wang Y, Erdmann N, Giannone RJ, Wu J, Gomez M, Liu Y. An increase in telomere sister chromatid exchange in murine embryonic stem cells possessing critically shortened telomeres. Proc Natl Acad Sci USA 2005; 102: 10256-10260. (Pubitemid 41023359)
34. Krizhanovsky V, Lowe SW. Stem cells: The promises and perils of p53. Nature 2009; 460: 1085-1086.
35. Tapia N, Scholer HR. p53 connects tumorigenesis and reprogramming to pluripotency. J Exp Med 2010; 207: 2045-2048.
36. Carter MG, Stagg CA, Falco G, et al. An in situ hybridizationbased screen for heterogeneously expressed genes in mouse ES cells. Gene Expr Patterns 2008; 8: 181-198.
37. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010; 143: 508-525.
38. Wang F, Yin Y, Ye X, et al. Molecular insights into the heterogeneity of telomere reprogramming in induced pluripotent stem cells. Cell Res 2012; 22: 757-768.
39. De Boeck G, Forsyth RG, Praet M, Hogendoorn PC. Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J Pathol 2009; 217: 327-344.
40. Jain D, Cooper JP. Telomeric strategies: means to an end. Annu Rev Genet 2010; 44: 243-269.
41. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25-34. (Pubitemid 27431310)
42. Jiang J, Ding G, Lin J, et al. Different developmental potential of pluripotent stem cells generated by different reprogramming strategies. J Mol Cell Biol 2011; 3: 197-199.
43. Li J, Mombaerts P. Nuclear transfer-mediated rescue of the nuclear genome of nonviable mouse cells frozen without cryoprotectant. Biol Reprod 2008; 79: 588-593.
44. Eggan K, Akutsu H, Loring J, et al. Hybrid vigor, fetal overgrowth, and viability of mice derived by nuclear cloning and tetraploid embryo complementation. Proc Natl Acad Sci USA 2001; 98: 6209-6214. (Pubitemid 32488218)
45. Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev 2010; 24: 2239-2263.
46. Chen T, Yuan D, Wei B, et al. E-cadherin-mediated cell-cell contact is critical for induced pluripotent stem cell generation. Stem Cells 2010; 28: 1315-1325.
47. Li W, Ding S. Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. Trends Pharmacol Sci 2010; 31: 36-45.
48. Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008; 26: 1276-1284.
49. Kim JB, Zaehres H, Wu G, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008; 454: 646-650.
50. Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small molecule compounds. Nat Biotechnol 2008; 26: 795-797. (Pubitemid 351961456)
51. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26: 1269-1275.
52. Shi Y, Do JT, Desponts C, Hahm HS, Scholer HR, Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008; 2: 525-528. (Pubitemid 351729222)
53. Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biology 2008; 6:e253.
54. Marson A, Foreman R, Chevalier B, et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell 2008; 3: 132-135.
55. Darabi R, Arpke RW, Irion S, et al. Human ES-and iPSderived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell 2012; 10: 610-619.
56. Cheng L, Hansen NF, Zhao L, et al. Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell 2012; 10: 337-344.
57. Liu L, Bailey SM, Okuka M, et al. Telomere lengthening early in development. Nat Cell Biol 2007; 9: 1436-1441. (Pubitemid 350201757)
58. Tanemura K, Ogura A, Cheong C, et al. Dynamic rearrangement of telomeres during spermatogenesis in mice. Dev Biol 2005; 281: 196-207. (Pubitemid 40719147)
59. Marion RM, Strati K, Li H, et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell 2009; 4: 141-154.
60. Huang J, Wang F, Okuka M, et al. Association of telomere length with authentic pluripotency of ES/iPS cells. Cell Res 2011; 21: 779-792.
61. Siegl-Cachedenier I, Flores I, Klatt P, Blasco MA. Telomerase reverses epidermal hair follicle stem cell defects and loss of long-term survival associated with critically short telomeres. J Cell Biol 2007; 179: 277-290. (Pubitemid 350004892)
62. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676. (Pubitemid 44233629)